UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549
                                -----------------

                                    FORM 10Q
                                -----------------
(Mark One)
 [ X ]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
            EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2013

[ ]         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE
            ACT
            For the transition period from __________ to ___________

                       Commission file number: 333-174853

                               GLOBAL GREEN, INC.
                               ------------------
             (Exact name of registrant as specified in its charter)

         Florida                                            20-1515998
         -------                                            ----------
(State of Incorporation)                               (IRS Employer ID Number)

             2820 Remington Green Circle, Tallahassee, Florida 32308
             -------------------------------------------------------
                    (Address of principal executive offices)

                                  850-597-7906
                                  ------------
                         (Registrant's Telephone number)


            (Former Address and phone of principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter  period that the registrant was required
to file such reports),  and (2) has been subject to the filing  requirements for
the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted  pursuant to Rule 405 for Regulation S-T  (ss.232.405
of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes [ X ] No []

Indicate by check mark whether the  registrant is a large  accelerated  file, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
the definitions of "large accelerated  filer,"  "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large  accelerated  filer [ ] Accelerated  filer [ ]  Non-accelerated  filer [ ]
Smaller reporting company [X] (Do not check if a smaller reporting company)


<PAGE>



Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate  the number of share  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

As of August 12, 2013, there were 745,761,432 shares of the registrant's  common
stock issued and outstanding.




<PAGE>
<TABLE>
<CAPTION>
<S>                                                                             <C>



PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements       (Unaudited)                                                Page
                                                                                               ----

         Balance Sheets - June 30, 2013 and December 31, 2012 (Audited)                          1

         Statements of Operations  -
                  Three and Six months ended June 30, 2013 and 2012 and
                  From Inception (July 12, 2004) to June 30, 2013                                2

         Statements of Changes in Shareholders' Equity -
                   From Inception (July 12, 2004) to June 30, 2013                               3

         Statements of Cash Flows -
                  Six months ended June 30, 2013 and 2012 and
                  From Inception (July 12, 2004) to June 30, 2013                                4

         Notes to the Financial Statements                                                       5

Item 2.  Management's Discussion and Analysis of Financial Condition
                  and Results of Operations                                                      12

Item 3.  Quantitative and Qualitative Disclosures About Market Risk                              16
                  - Not Applicable

Item 4. Controls and Procedures                                                                  16

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings -Not Applicable                                                       16

Item 1A.  Risk Factors -  Not Applicable                                                         16

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds                             17
-        Not Applicable

Item 3.  Defaults Upon Senior Securities - Not Applicable                                        17

Item 4.  Mine Safety Disclosure - Not Applicable                                                 17

Item 5.  Other Information - Not Applicable                                                      17

Item 6.  Exhibits                                                                                17
SIGNATURES                                                                                       18
</TABLE>

<PAGE>




                                     PART I

ITEM 1. FINANCIAL STATEMENTS


<PAGE>


<PAGE>
<TABLE>
<CAPTION>


                            GLOBAL GREEN, INC.
                      (A Development Stage Company)
                        Consolidated Balance Sheet
                   June 30, 2013 and December 31, 2012
<S>                                                                            <C>


                                                                               June 30,               December 31, 2012
                                                                                 2013
                                                                           ------------------   ------------------------------
ASSETS
Current assets
Cash and cash equivalents                                                          $ 242,546              $ 4,027
Prepaid expenses                                                                         750                1,125
                                                                           ------------------   ------------------
Total current assets                                                                 243,296                5,152

Intangible asset, net                                                                  5,963                6,131
                                                                           ------------------   ------------------

Total assets                                                                       $ 249,259             $ 11,283
                                                                           ------------------   ------------------

LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses                                               $ 19,642             $ 30,180
Due to shareholders                                                                      500                  500
Convertible advance- related party                                                   300,000                    -
                                                                           ------------------   ------------------
Total liabilities                                                                    320,142               30,680
                                                                           ------------------   ------------------
Shareholders' deficit:
Preferred stock; no par value; 100,000,000                                                 -                    -
      shares authorized; no shares outstanding at
      June 30, 2013 or December 31, 2012
Common stock; $.00001 par value; 3,000,000,000                                         7,458                7,458
      shares authorized; 745,761,432 shares issued and
outstanding at June 30, 2013 or December 31, 2012
Additional paid in capital                                                           285,573              285,573
Deficit accumulated during the development stage                                    (363,914)            (312,428)
                                                                           ------------------   ------------------
       Total shareholders' deficit                                                   (70,883)             (19,397)
                                                                           ------------------   ------------------
Total liabilities and shareholders' deficit                                        $ 249,259             $ 11,283
                                                                           ------------------   ------------------


             See accompanying Notes to Financial Statements.
</TABLE>

                                       1

<PAGE>
<TABLE>
<CAPTION>

                               GLOBAL GREEN, INC.
                          (A Development Stage Company)
                      Consolidated Statement of Operations
      For the Six and Three Months Ended June 30, 2013 and 2012 and For the
            Period of Inception (July 12, 2004) Through June 30, 2012
                                   (Unaudited)
<S>                                                                             <C>


                                                                  Six months ended June 30,             Three months ended June 30,
                                                                2013                    2012                    2013
                                                         --------------------    --------------------    --------------------

REVENUES                                                         $         -               $       -              $        -
                                                         --------------------    --------------------    --------------------
OPERATING EXPENSES
   Testing for U.S. Department of                                          -                       -                       -
       Agriculture's approval
   Professional fees                                                  15,022                  45,145                  17,892
   General and administrative                                         27,660                  13,782                  10,818
   Consulting fees                                                         -                   5,000                       -
   Stock transfer agent fees                                           1,085                     882                     485
   Interest expense                                                    7,500                       -                   3,750
   Amortization                                                          168                     168                      84
   Bank fees                                                              51                      50                      25
                                                         --------------------    --------------------    --------------------
        Total operating expenses                                      51,486                  65,027                  33,054
                                                         --------------------    --------------------    --------------------
NET LOSS                                                           $ (51,486)              $ (65,027)              $ (33,054)
                                                         --------------------    --------------------    --------------------

 Net loss per share applicable to common                              $(0.00)                $ (0.00)                 $(0.00)
   stockholders-- basic and diluted
                                                         --------------------    --------------------    --------------------
 Weighted average number of shares                               745,761,432             745,761,432             745,761,432
   outstanding - basic and diluted
                                                         --------------------    --------------------    --------------------

    See accompanying Notes to Financial Statements.


</TABLE>
                                       2
<PAGE>
<TABLE>
<CAPTION>

                               GLOBAL GREEN, INC.
                          (A Development Stage Company)
                      Consolidated Statement of Operations
      For the Six and Three Months Ended June 30, 2013 and 2012 and For the
            Period of Inception (July 12, 2004) Through June 30, 2012
                                   (Unaudited)
(continued)

<S>                                                                             <C>


                                  Three months ended June 30,   Inception to June 30, 2013
                                            2012
                                  --------------------------    --------------------------
REVENUES                                     $           -              $        -
                                       --------------------    --------------------
OPERATING EXPENSES
   Testing for U.S. Department of                        -                 137,800
       Agriculture's approval
   Professional fees                                19,841                 142,024
   General and administrative                       11,304                  57,685
   Consulting fees                                   5,000                  10,200
   Stock transfer agent fees                           732                   7,687
   Interest expense                                                          7,500
   Amortization                                         84                     868
   Bank fees                                            50                     150
                                       --------------------    --------------------
        Total operating expenses                    37,011                 363,914
                                       --------------------    --------------------
NET LOSS                                         $ (37,011)             $ (363,914)
                                       --------------------    --------------------

 Net loss per share applicable to common           $ (0.00)
   stockholders-- basic and diluted
                                       --------------------
 Weighted average number of shares             745,761,432
   outstanding - basic and diluted
                                       --------------------

    See accompanying Notes to Financial Statements.

</TABLE>

                                       3


<PAGE>
<TABLE>
<CAPTION>


                               GLOBAL GREEN, INC.
                          (A Development Stage Company)
                        Consolidated Statement of Equity
        For the Period of Inception (July 12, 2004) Through June 30, 2013
                                   (Unaudited)
<S>                                                                             <C>

                                                                                      Accumulated
                                                                                      During the        Total
                                               Common       Common    Additional      Development    Shareholders'
                                               Shares       Stock    Paid in Capital     Stage          Deficit
                                            -------------   ---------  --------------------------   -------------
INCEPTION, July 12, 2004                               -         $ -             $ -         $ -             $ -

   Share issuance, September 2004              3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2004                     3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2005                     3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2006                     3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2007                     3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2008                     3,141,597         314            (314)          -               -
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2009                     3,141,597         314            (314)          -               -

   Recapitalization due to 10 to 1
      stock split28,274,370                            -            -              -           -               -
   Stock based compensation                   20,000,000         200               -           -             200
   Share issuance                            683,097,847       6,831               -           -           6,831

Net loss                                               -           -               -      (5,728)         (5,728)
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2010                   734,513,814       7,345            (314)     (5,728)          1,303

   Share issuance                             11,247,618         113         285,887           -         286,000

Net loss                                               -           -               -    (191,800)       (191,800)
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2011                   745,761,432       7,458         285,573    (197,528)         95,503

Net loss                                               -           -               -    (114,900)       (114,900)
                                            -------------   ---------  --------------------------   -------------
BALANCE, December 31, 2012                   745,761,432       7,458         285,573    (312,428)        (19,397)

Net loss                                               -           -               -     (51,486)        (51,486)
                                            -------------   ---------  --------------------------   -------------
BALANCE, June 30, 2013                       745,761,432     $ 7,458       $ 285,573  $ (363,914)      $ (70,883)
                                            -------------   ---------  --------------------------   -------------

         See accompanying Financial Statements.

</TABLE>

                                       4
<PAGE>
<TABLE>
<CAPTION>


                               GLOBAL GREEN, INC.
                          (A Development Stage Company)
                      Consolidated Statements of Cash Flow
               For the Six Months Ended June 30, 2013 and 2012 and
        For the Period of Inception (July 12, 2004) through June 30, 2013
                                   (Unaudited)
<S>                                                                             <C>


                                                                    June 30,            June30,         Inception to June 30,
                                                                      2013               2012                  2013
                                                              -----------------    ------------------   -------------------

CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss                                                           $ (51,486)            $ (65,027)           $ (363,914)
  Adjustments to reconcile net loss to net cash
    from operating activities:
         Amortization                                                      168                   168                   868
         Stock based compensation                                            -                     -                   200
       Change in assets and liabilities:
Prepaid expenses                                                           375                 2,126                  (750)
Accounts payable and accrued expenses                                  (10,538)                6,095                19,642
         Due to shareholders                                                 -                     -                   500
                                                              -----------------    ------------------   -------------------
Net cash from operating activities                                     (61,481)              (56,638)             (343,454)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from share issuance                                                 -                     -               286,000
Proceeds from convertible advance -                                    300,000                     -               300,000
    related party
                                                              -----------------    ------------------   -------------------
Net cash from financing activities                                     300,000                     -               586,000


NET CHANGE IN CASH                                                     238,519               (56,638)              242,546
CASH, beginning of period                                                4,027               103,360                     -
                                                              -----------------    ------------------   -------------------
CASH, end of period                                                  $ 242,546              $ 46,722             $ 242,546
                                                              -----------------    ------------------   -------------------


SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES:
    Common stock issued for acquisition of
        Global Green International, Inc.                                   $ -                  $ -                $ 6,831
                                                              -----------------    ------------------   -------------------
       See accompanying Notes to Financial Statements.

</TABLE>

                                       5
<PAGE>


                          (A Development Stage Company)
                 Notes To The Consolidated Financial Statements
                                  June 30, 2013
                                   (Unaudited)

NOTE 1   NATURE OF ORGANIZATION

               Global  Green,  Inc.  (the  "Company")  is a Florida  Corporation
               incorporated  on July 12, 2004 as a wholly  owned  subsidiary  of
               Global Assets & Services, Inc. In September 2004, the Company was
               spun out into a separate  legal entity.  The Company  changed its
               name from The Global Tech Assets,  Inc. to Global Green,  Inc. in
               April 2010 and its fiscal period end is December 31.

               The Company is in the development stage. The principal activities
               during the  development  stage include  organizing  the corporate
               structure,  implementing the Company's  business plan and raising
               capital. Although the Company was formed in 2004, it did not have
               any operating activities until 2010.

               Under the Share Exchange Agreement executed on November 29, 2010,
               between  the  Company  and  Nutritional  Health  Institute,   LLC
               ("NHIL"), the Company acquired 100% of the issued and outstanding
               stock of Global  Green  International,  Inc.  ("GGII"),  a wholly
               owned  subsidiary of NHIL. At the same time,  the Company  issued
               approximately   683   million   shares  of  its   common   stock,
               representing 93% of the ownership of the Company,  to NHIL. After
               the  above  mentioned  acquisition  as  per  the  Share  Exchange
               Agreement, the Company has become a majority-owned  subsidiary of
               NHIL.  As the  effective  control  over GGII did not  change,  in
               accordance with Financial  Accounting  Standards Board's ("FASB")
               Accounting   Standards    Codification   ("ASC")   805   Business
               Combinations,  GGII is  consolidated  at its book value (See Note
               4). Prior to November 2010, GGII had no assets or operations,  so
               there is no impact to the historical financial statements.

               GGII, a wholly-owned  subsidiary of the Company, has been granted
               the exclusive  worldwide  rights (the  "Licensing  Agreement") to
               manufacture, distribute, market and sell a Salmonella Antigen and
               Vaccine (the  "Vaccine").  The  Licensing  Agreement was executed
               between  NHIL and  GGII  before  the  Company  acquired  the 100%
               ownership of GGII and is the only asset of GGII.

               In February  2011,  the Vaccine has been  entered  into the final
               phase of  becoming  a United  States  Department  of  Agriculture
               ("USDA")  approved  vaccine for the in ovo vaccination of chicken
               eggs to provide  immunity  against  Salmonella  bacteria.  In May
               2011,  the United States Patent and  Trademark  Office  granted a
               patent for the method and  composition in the Vaccine.  In August
               2011, an additional patent was granted related to the vaccine.


NOTE 2   GOING CONCERN

               These consolidated  financial  statements have been prepared on a
               going concern basis which  contemplates the realization of assets
               and the  satisfaction  of  liabilities  in the  normal  course of
               business for the  foreseeable  future.  As of June 30, 2013,  the
               Company has incurred net losses of $363,914 since inception (July
               12, 2004).

               Management's  plans include  raising  capital  through the equity
               markets to fund  operations  and  eventually,  the  generating of
               revenue through its business;  however, there can be no assurance
               that the Company will be  successful  in such  activities.  These
               consolidated  financial statements do not include any adjustments
               relating  to  the  recovery  of  the   recorded   assets  or  the
               classifications of the liabilities that might be necessary should
               the Company be unable to continue as a going concern.

                                       6


<PAGE>




NOTE 3   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

               Basis of Presentation

               The  consolidated  financial  statements  have been  prepared  in
               accordance with accounting  principles  generally accepted in the
               United  States  of  America  ("GAAP")  on the  accrual  basis  of
               accounting.    All   significant    intercompany   accounts   and
               transactions have been eliminated in  consolidation.  The interim
               financial  statements reflect all adjustments,  which are, in the
               opinion of  management,  necessary in order to make the financial
               statements not misleading.

               Use of Estimates

               The  preparation of financial  statements in conformity with GAAP
               requires   management  to  adopt  accounting  policies  and  make
               estimates and  assumptions  that affect  amounts  reported in the
               financial  statements.   The  significant   accounting  policies,
               estimates  and  related   judgments   underlying   the  Company's
               financial  statements  are  summarized  below.  In applying these
               policies,  management makes subjective  judgments that frequently
               require estimates about matters that are inherently uncertain.

               Cash and Cash Equivalents

               The Company  considers  all  investments  with a maturity date of
               three months or less when purchased to be cash equivalents. There
               were no cash equivalents at June 30, 2013 and December 31, 2012.

               Revenue Recognition

               The Company recognizes revenue on arrangements in accordance with
               Securities  and Exchange  Commission  Staff  Accounting  Bulletin
               Topic 13, Revenue  Recognition  and FASB ASC  605-15-25,  Revenue
               Recognition.  In all cases,  revenue is recognized  only when the
               price  is  fixed  or  determinable,  persuasive  evidence  of  an
               arrangement  exists,  the service is performed and collectability
               is  reasonably  assured.  The Company did not report any revenues
               from inception to June 30, 2013.

               Earnings Per Share

               The Company has adopted ASC 260-10-50,  Earnings Per Share, which
               provides for  calculation  of "basic" and "diluted"  earnings per
               share.  Basic  earnings  per share  includes no  dilution  and is
               computed  by  dividing  net  income or loss  available  to common
               shareholders  by the weighted  average common shares  outstanding
               for the period.  Diluted earnings per share reflect the potential
               dilution of  securities  that could  share in the  earnings of an
               entity.  Basic and diluted  losses per share were the same at the
               reporting  dates  as  there  were  no  common  stock  equivalents
               outstanding at June 30, 2013 and December 31, 2012.

               Concentrations

               Financial  instruments  that  potentially  subject the Company to
               concentrations of credit risk consist principally of cash.

               Occasionally,  cash  balances may exceed  amounts  insured by the
               Federal Deposit Insurance Corporation ("FDIC").  Accordingly, the
               Company  places  its  cash and cash  equivalents  with  financial
               institutions  considered  by  management  to  be of  high  credit
               quality.  At times,  the Company's cash balances may be in excess
               of the FDIC limits.

                                       7
<PAGE>




               Fair Value of Financial Instruments

               The Company adopted Statement of Financial  Accounting  Standards
               ("SFAS") No. 157 Fair Value Measurements ("SFAS 157"), superseded
               by ASC 820-10, which defines fair value,  establishes a framework
               for measuring fair value and expands  required  disclosure  about
               fair value measurements of assets and liabilities.  The impact of
               adopting  ASC  820-10  was  not   significant  to  the  Company's
               financial  statements.  ASC  820-10  defines  fair  value  as the
               exchange  price  that would be  received  for an asset or paid to
               transfer a  liability  (an exit price) in the  principal  or most
               advantageous  market  for the asset or  liability  in an  orderly
               transaction  between market participants on the measurement date.
               ASC  820-10  also  establishes  a  fair  value  hierarchy,  which
               requires an entity to maximize the use of  observable  inputs and
               minimize  the use of  unobservable  inputs  when  measuring  fair
               value. The standard  describes three levels of inputs that may be
               used to measure fair value:

               Level 1 -  Valuation  based on  quoted  market  prices  in active
               markets for identical assets or liabilities.

               Level 2 -  Valuation  based on quoted  market  prices for similar
               assets and liabilities in active markets.

               Level  3 -  Valuation  based  on  unobservable  inputs  that  are
               supported by little or no market  activity,  therefore  requiring
               management's best estimate of what market  participants would use
               as fair value.

               In  instances   where  the   determination   of  the  fair  value
               measurement is based on inputs from different  levels of the fair
               value  hierarchy,  the level in the fair value  hierarchy  within
               which the  entire  fair value  measurement  falls is based on the
               lowest  level  input  that  is  significant  to  the  fair  value
               measurement in its entirety.  Our assessment of the  significance
               of a  particular  input  to the  fair  value  measurement  in its
               entirety requires judgment, and considers factors specific to the
               asset or liability.  The valuation of our derivative liability is
               determined  using Level 1 inputs,  which consider (i) time value,
               (ii) current market and (iii) contractual prices.

               Fair value  estimates  discussed  herein  are based upon  certain
               market  assumptions  and  pertinent   information   available  to
               management  as of June  30,  2013  and  December  31,  2012.  The
               respective carrying value of certain  on-balance-sheet  financial
               instruments  approximated their fair values due to the short-term
               nature of these instruments.  These financial instruments include
               cash, accounts payable, accrued expenses and advance.


               Income Taxes

               Deferred tax assets and liabilities are recognized for the future
               tax   consequences   attributable  to  differences   between  the
               financial  statement  carrying  amounts  of  existing  assets and
               liabilities  and their  respective tax bases.  Additionally,  the
               recognition  of future tax benefits,  such as net operating  loss
               carryforwards, is required to the extent that realization of such
               benefits  is more  likely  than  not.  Deferred  tax  assets  and
               liabilities  are  measured  using  enacted tax rates  expected to
               apply to  taxable  income in the years in which  the  assets  and
               liabilities  are expected to be recovered or settled.  The effect
               on deferred tax assets and  liabilities  of a change in tax rates
               is  recognized  in income tax expense in the period that includes
               the enactment date.

               In the event the future tax  consequences of differences  between
               the financial  reporting bases and the tax bases of the Company's
               assets  and  liabilities   result  in  deferred  tax  assets,  an
               evaluation of the probability of being able to realize the future
               benefits  indicated  by  such  asset  is  required.  A  valuation
               allowance  is provided  for the portion of the deferred tax asset
               when it is more likely than not that some or all of the  deferred
               tax asset will not be realized. In assessing the realizability of
               the  deferred  tax assets,  management  considers  the  scheduled
               reversals of deferred tax  liabilities,  projected future taxable
               income, and tax planning strategies.


                                       8
<PAGE>





               The Company  files  income tax  returns in the United  States and
               Florida,  which are subject to examination by the tax authorities
               in these  jurisdictions.  Generally,  the statute of  limitations
               related to the  Company's  federal and state income tax return is
               three years.  The state  impact of any federal  changes for prior
               years  remains  subject  to  examination  for a period up to five
               years after formal notification to the states.


               Management  has evaluated  tax positions in accordance  with FASB
               ASC 740, Income Taxes, and has not identified any significant tax
               positions, other than those disclosed.

               Subsequent Events

               In accordance with FASB ASC 855,  Subsequent  Events, the Company
               evaluated  subsequent events through August 4, 2013, the date the
               financial statements were available for issue.


NOTE 4   INTANGIBLE ASSET

               The Company  accounts for its intangible asset in accordance FASB
               ASC 350  Intangibles--Goodwill  and Other. The intangible  assets
               consist of the Licensing Agreement and is carried at an allocated
               cost, less accumulated amortization.  The Licensing Agreement was
               executed on November 29, 2010  between NHIL and GGII,  before the
               Company  acquired the 100% ownership of GGII as described in Note
               1. The provisions in the License  Agreement include the Company's
               responsibilities to protect the Vaccine information and to assume
               financial  responsibilities  for the acquisition of USDA approval
               of the Vaccine. The License Agreement has no expiration date, but
               is being  amortized  over the 20 year legal  life of the  related
               patent.  As the effective  control over GGII did not change after
               acquisition  by the  Company,  in  accordance  with FASB ASC 805,
               Business  Combinations,  the License Agreement is consolidated at
               the book value.


               Components  of  intangible  assets  at the  periods  ended are as
follows:

                                            June 30,           December 31,
                                              2013                 2012
                                       -------------------- --------------------
License agreement                                $   6,831            $   6,831
Accumulated amortization                             (868)                (700)
                                       -------------------- --------------------
                                                 $   5,963            $   6,131
                                       -------------------- --------------------

NOTE 5   TAXES

               The components of income tax expense for the periods ended are as
follows:

<TABLE>
<CAPTION>
<S>                                                                             <C>

                                                                                                        Inception to
                                                                                                          June 30,
                                                               June 30, 2013      June 30, 2012             2013
                                                             ------------------ ------------------- ---------------------
             Current tax benefit                             $        (19,359)  $       (24,450)    $(136,833)
             Change in valuation allowance                             19,359            24,450       136,833
                                                             ------------------ ------------------- ---------------------
                                                             $            -     $           -      $     -
                                                             ------------------ ------------------- ---------------------

</TABLE>


                                       9


<PAGE>





               The difference  between  income tax expense  computed by applying
               the statutory  federal  income tax rate to earnings  before taxes
               for the periods ended are as follows:

<TABLE>
<CAPTION>
<S>                                                                             <C>


                                                                                                        Inception to June
                                                                                                               30,
                                                                                                               2013
                                                                   June 30, 2013      June 30, 2012        (Unaudited)
                                                                 ------------------ ------------------ --------------------
             Pretax loss at federal statutory rate               $ ( 17,506)         $   (22,109)       $    (123,733)
             State income benefit, net of federal benefit            (1,853)              (2,341)             (13,100)
             Change in valuation allowance                           19,359               24,450              136,833
                                                                 ------------------ ------------------ ------------------
                                                                 $       -           $         -        $        -
                                                                 ------------------ ------------------ --------------------
</TABLE>


               The components of deferred taxes are as follows:



                                            June 30,           December 31,
                                              2013                 2012
                                       -------------------- --------------------
Deferred income tax assets:
   Operating loss carryforwards                $   136,833          $   117,474
   Less: valuation allowance                      (136,833)            (117,474)
                                       -------------------- --------------------
Net deferred tax asset                            $      -             $      -
                                       -------------------- --------------------


               At June 30, 2013 and December 31, 2012, a valuation allowance was
               established  for the entire  amount of the net deferred tax asset
               as the  realization  of the  deferred  tax asset is  dependent on
               future taxable income.

               At  June  30,   2013,   the  Company  had  net   operating   loss
               carryforwards  for tax  purposes of  $363,914,  which will expire
               beginning in 2031, if not previously utilized.


NOTE 6   EQUITY

               In April  2010,  the  Company  authorized  the  issuance of up to
               100,000,000 shares of Preferred Stock at no par value. As of June
               30,  2013  and  December  31,  2012,  no  shares  are  issued  or
               outstanding.

               In May 2010,  the  Company  had a 10-to-1  stock  forward  split,
               changing  its par value  from  $.0001  per share to  $.00001  per
               share.  Right  after the said stock  split,  the  Company  issued
               20,000,000 shares of its common stock to certain shareholders for
               services  rendered valued at $200. This is recorded as a non-cash
               expense in the accompanying statement of operations.

               In November 2010, the Company  issued  approximately  683 million
               shares of common stock,  representing 93% of the ownership of the
               Company, to NHIL. After the above mentioned issuance, the Company
               has become a majority-owned subsidiary of NHIL.

               On March 21, 2011, the Company  completed a private  placement of
               common  stock to  accredited  investors  and raised  $286,000  of
               working capital.

                                       10

<PAGE>




NOTE 7   RELATED PARTY TRANSACTIONS AND COMMITMENTS

               On January 2013, the Company  entered into a convertible  advance
               with the Company's  Chief  Executive  Officer and  Chairman.  The
               convertible  advance,  with  a  face  value  of  $300,000,  bears
               interest  at  5%  per  annum  and  is  payable  on  demand.   The
               convertible advance is convertible,  at the holder's option, into
               the  Company's  common or preferred  shares based on the value of
               the shares at the execution date of the advance.  The convertible
               advance is valued at the greater of the face value of the advance
               or the fair value of the shares,  if converted.  At June 30, 2013
               and December 31, 2012, the convertible  advance,  was recorded at
               $300,000 and $0,  respectively.  Accrued interest related to this
               advance was $7,500 and $0 at June 30, 2013 and December 31, 2012,
               respectively,  and is included  in  accounts  payable and accrued
               expenses on the balance sheet.

               Through  its  wholly-owned  subsidiary,  GGII,  the  Company  has
               exclusive  rights  to the  Licensing  Agreement  with  NHIL,  the
               Company's   majority   shareholder.   In  accordance   with  this
               agreement,  GGII  assumes the  financial  responsibility  for the
               acquisition  and  maintenance  of all patents,  as well as USDA's
               approval of the Vaccine.


  NOTE 8     CONTINGENCIES

               During the normal course of business,  the Company may be exposed
               to  litigation.  When the  Company  becomes  aware  of  potential
               litigation,  it  evaluates  the merits of the case in  accordance
               with FASB ASC 450-20-50, Contingencies. The Company evaluates its
               exposure to the matter,  possible legal or settlement  strategies
               and the  likelihood  of an  unfavorable  outcome.  If the Company
               determines  than an  unfavorable  outcome is probable  and can be
               reasonably  estimated,  it establishes the necessary accruals. As
               of June 30,  2013,  the  Company  is not aware of any  contingent
               liabilities   that  should  be  reflected  in  the   accompanying
               financial statements.


                                       11

<PAGE>







ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

The  following  discussion  should  be read in  conjunction  with our  unaudited
financial  statements and notes thereto included herein. In connection with, and
because we desire to take  advantage  of, the "safe  harbor"  provisions  of the
Private  Securities  Litigation Reform Act of 1995, we caution readers regarding
certain forward looking statements in the following  discussion and elsewhere in
this report and in any other statement made by, or on our behalf, whether or not
in future filings with the Securities and Exchange  Commission.  Forward-looking
statements are statements not based on historical  information  and which relate
to future  operations,  strategies,  financial  results  or other  developments.
Forward looking  statements are necessarily based upon estimates and assumptions
that are inherently  subject to significant  business,  economic and competitive
uncertainties and  contingencies,  many of which are beyond our control and many
of which,  with  respect to future  business  decisions,  are subject to change.
These  uncertainties and contingencies can affect actual results and could cause
actual results to differ  materially from those expressed in any forward looking
statements  made by, or on our behalf.  We  disclaim  any  obligation  to update
forward-looking statements.

The  independent  registered  public  accounting  firm's report on the Company's
financial  statements as of December 31, 2012,  and for each of the years in the
two-year period then ended,  includes a "going concern"  explanatory  paragraph,
that describes  substantial  doubt about the Company's  ability to continue as a
going concern.

PLAN OF OPERATIONS

We had no  operations  prior to  January  2009 and we did not have any  revenues
during the quarter  ended June 30, 2013 nor the fiscal years ended  December 31,
2012 and 2011. We have minimal  capital,  minimal cash,  and only our intangible
assets  consist  of  our  patents  and  patent   applications,   business  plan,
relationships  and  contacts.  We are  illiquid  and need  cash  infusions  from
investors or shareholders to provide capital, or loans from any sources.

In March 2012, the Company  completed its Final  Efficacy  Testing and submitted
the  results  to the  USDA and are  awaiting  a  response  from  the  USDA.  Our
continuing plan of operations will be as follows:

Milestones

3rd  Quarter 2013

o        Continuing Market Development.
o        Manufacturing vaccine batch for the final Efficacy study.
o        Perform USDA regulatory  Efficacy Study and Potency Testing  according
         to Model Test.

4tht Quarter 2013

o    First USDA product licensing submission.
o    USDA creates product file and assigns a Product Code.
o    Initiate Vaccine  Manufacturing  Setup for USDA approved  protocol efficacy
     testing.

                                       12
<PAGE>




1st Quarter 2014

o    USDA Product Outline Review
o    Submission  of  Master  Seed to  NVSL  (USDA/National  Veterinary  Services
     Laboratories) for testing.
o    Manufacturing Vaccine batch for Final Efficacy Testing.
o    Second USDA product licensing submission with Efficacy Study report.
o    Third USDA product licensing  submission with Field Safety Report and final
     labeling.
o    Vaccine   Manufacturer   is  authorized  to  submit  samples  to  NVSL  for
     confirmatory testing.

The Company's status regarding its Phase 4 efficacy testing is:

o    In the process of negotiating with an USDA approved vaccine manufacturer.
o    Assure that the requirements  from the vaccine  manufacturer  will meet the
     standard  batch  consistency as defined by the USDA as part of the efficacy
     requirements.

o    The conclusion of the USDA approved large bird efficacy study to be done by
     AHPharma which meets the following parameters:
o    That the vaccine product can be safely and standardly  commercially applied
     by the intended customers.
o    That the claims are  sustainable  and  reproducible  when applied to larger
     populations of birds.
o    To see if the vaccine can be used in other circumstances such as a combined
     treatment  with other  vaccines.  This part of the study has been completed
     and proven successful.
o    Presentation  of the data of the  efficacy  tests to be  analyzed  and send
     results to the USDA for final approval.

In August 2012, the Company began a study to determine how long a chicken can be
protected against  Salmonella after it begins laying eggs. If a layer hen is not
infected with the Salmonella bacteria, then neither the egg, nor the chick, when
it hatches,  will have  Salmonella.  There is a "timelined"  vaccine effect that
will be logged and sequenced  during the study,  beginning from a  newly-hatched
chicken,  to the 18-20 weeks before the chicken  becomes a layer hen, and, after
that, until the end of the hen's productive life.

In January  2013,  the  Company  entered  into a  convertible  advance  with the
Company's Chief Executive  Officer and Chairman,  Dr. Ghazvini.  The convertible
advance  with a face value of  $300,000,  bears  interest at 5% per annum and is
payable on demand.  The  convertible  advance is  convertible,  at the  holder's
option,  into the Company's common or preferred shares based on the value of the
shares at the execution date of the advance.  At June 30, 2013, the  convertible
advance was recorded at $300,000.  Accrued  interest related to this advance was
$7,500 at June 30, 2013 and is included in accounts payable and accrued expenses
on the balance sheet.

We will need  substantial  additional  capital to support  our  proposed  future
operations. We have no revenues. We have no committed source for any funds as of
date hereof.  No  representation  is made that any funds will be available  when
needed.  In the event funds cannot be raised when needed,  we may not be able to
carry out our business plan, may never achieve sales, and could fail in business
as a result of these uncertainties.

                                       13
<PAGE>




RESULTS OF OPERATIONS

For the Three Months Ended June 30, 2013 Compared to the Three Months Ended June
30, 2012

During  the three  months  ended June 30,  2013 and 2012,  the  Company  did not
recognize  any revenues  from it  operational  activities.  Management  does not
anticipate  recognizing  any revenues from the sale of the  Salmogenic  vaccine,
until the final  approval of the USDA has been granted and that time the Company
will be able to begin sales and marketing efforts.

During the three months ended June 30, 2013,  the Company  incurred  operational
expenses of $33,054.  During the three months  ended June 30, 2012,  the Company
incurred  operational  expenses of $37,011. The decrease of $3,957 was primarily
a result  of a $5,000  decrease  in  consulting  fees,  a $1,949  decrease   in
professional  fees, a decrease of $486 in general and  administrative  expenses,
offset by a $3,750  increase in interest  expense.  The decrease in professional
fees was a result of the Company's  completion of its successful  efforts to get
its common stock  listed for trading with FINRA and for holding with  Depository
Trust in the early part of 2012.

During the three months ended June 30, 2013,  the Company  recognized a net loss
of $33,054  compared to a net loss of $37,011 during the three months ended June
30,  2012.  The  decrease  of  $3,957  was a direct  result of the  decrease  in
operational expenses discussed above.

For the Six Months Ended June 30, 2013 Compared to the Six Months Ended June 30,
2012

During  the six  months  ended  June 30,  2013 and  2012,  the  Company  did not
recognize  any revenues  from it  operational  activities.  Management  does not
anticipate  recognizing  any revenues from the sale of the  Salmogenic  vaccine,
until the final  approval of the USDA has been granted and that time the Company
will be able to begin sales and marketing efforts.

During the six months  ended June 30,  2013,  the Company  incurred  operational
expenses  of $51,486.  During the six months  ended June 30,  2012,  the Company
incurred  operational expenses of $65,027. The decrease of $13,541 was primarily
a result of a $5,000  decrease  in  consulting  fees and a $30,123  decrease  in
professional fees offset by an increase of $13,878 in general and administrative
expenses,   and  a  $7,500  increase  in  interest  expense.   The  decrease  in
professional  fees was a result of the Company's  completion  of its  successful
efforts to get its common  stock  listed for trading  with FINRA and for holding
with Depository Trust in the early part of 2012.

During the six months ended June 30, 2013, the Company  recognized a net loss of
$51,486 compared to a net loss of $65,027 during the three months ended June 30,
2012. The decrease of $13,541 was a direct result of the decrease in operational
expenses discussed above.


LIQUIDITY

The  independent  registered  public  accounting  firm's report on the Company's
financial  statements as of December 31, 2012,  and for each of the years in the
two-year period then ended,  includes a "going concern"  explanatory  paragraph,
that describes  substantial  doubt about the Company's  ability to continue as a
going concern.

At June 30, 2013, the Company had total current  assets of $243,296,  consisting
of $242,546 in cash and prepaid  expenses of $750 and total current  liabilities
of $320,142,  consisting  of $19,642 in accounts  payable and accrued  expenses,
$500 due to shareholders and a $300,000 convertible advance to related party. At
June 30, 2013, the Company had working capital deficit of $76,846.

                                       14
<PAGE>





During the six months ended June 30, 2013,  the Company used $61,481 in funds in
it  operational  activities.  During the six months  ended March 31,  2013,  the
Company  recognized  a net  loss of  $51,486  which  was  adjusted  for  $168 in
amortization  expense.  During the six months ended June 30,  2012,  the Company
used  $56,638 in its  operations,  a net loss of $65,027  was  adjusted  for the
non-cash item of $168 in amortization expense.

During the six months ended June 30, 2013,  the Company  received  $300,000 from
its financing activities.

In January  2013,  the  Company  entered  into a  convertible  advance  with the
Company's Chief Executive  Officer and Chairman,  Dr. Ghazvini.  The convertible
advance,  with a face value of $300,000,  bears  interest at 5% per annum and is
payable on demand.  The  convertible  advance is  convertible,  at the  holder's
option,  into the Company's common or preferred shares based on the value of the
shares at the execution  date of the advance At June 30, 2013,  the  convertible
advance, was recorded at $300,000.  Accrued interest related to this advance was
$7,500 at June 30, 2013 and is included in accounts payable and accrued expenses
on the balance sheet.

Short Term

On a short-term  basis,  the Company has not  generated  any revenue or revenues
sufficient  to cover  operations.  For  short  term  needs the  Company  will be
dependent on receipt, if any, of offering proceeds.

Capital Resources

The Company has only common stock as its capital resource.

The Company has no material commitments for capital expenditures within the next
year, however if operations are commenced, substantial capital will be needed to
pay for  participation,  investigation,  exploration,  acquisition  and  working
capital.

Need for Additional Financing

The Company does not have capital sufficient to meet its cash needs. The Company
will have to seek  loans or equity  placements  to cover such cash  needs.  Once
manufacturing and sales efforts commence,  its needs for additional financing is
likely to increase substantially.

No  commitments  to provide  additional  funds  have been made by the  Company's
management or other  stockholders.  Accordingly,  there can be no assurance that
any  additional  funds will be available to the Company to allow it to cover the
Company's expenses as they may be incurred.

Significant Accounting Policies

Revenue Recognition

 The Company  recognizes  revenue on  arrangements in accordance with Securities
 and Exchange Commission Staff Accounting Bulletin Topic 13, Revenue Recognition
 and  FASB  ASC  605-15-25,  Revenue  Recognition.  In  all  cases,  revenue  is
 recognized only when the price is fixed or determinable, persuasive evidence of
 an  arrangement   exists,  the  service  is  performed  and  collectability  is
 reasonably  assured.  The Company did not report any revenues from inception to
 June 30, 2013.

                                       15
<PAGE>




 Earnings Per Share

 The Company has adopted ASC 260-10-50,  Earnings Per Share,  which provides for
 calculation  of "basic" and "diluted"  earnings per share.  Basic  earnings per
 share  includes  no dilution  and is  computed  by dividing  net income or loss
 available  to  common  shareholders  by  the  weighted  average  common  shares
 outstanding  for the period.  Diluted  earnings per share reflect the potential
 dilution of securities that could share in the earnings of an entity. Basic and
 diluted losses per share were the same at the reporting  dates as there were no
 common stock equivalents outstanding at June 30, 2013 or June 30, 2012.

ITEM 3.  QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable


ITEM 4.  CONTROLS AND PROCEDURES

Disclosures Controls and Procedures

We have adopted and maintain disclosure controls and procedures (as such term is
defined in Rules 13a 15(e) and 15d-15(e)  under the  Securities  Exchange Act of
1934,  as amended  (the  "Exchange  Act")) and that are  designed to ensure that
information  required to be disclosed in our reports  under the Exchange Act, is
recorded,  processed,  summarized and reported within the time periods  required
under  the  SEC's  rules and forms  and that the  information  is  gathered  and
communicated to our management, including our Chief Executive Officer (Principal
Executive Officer) and Chief Financial Officer (Principal Financial Officer), as
appropriate, to allow for timely decisions regarding required disclosure.

As required by SEC Rule 15d-15(b), our Chief Executive/Financial Officer carried
out an  evaluation  under  the  supervision  and with the  participation  of our
management,  of the  effectiveness of the design and operation of our disclosure
controls  and  procedures  pursuant to Exchange Act Rule 15d-14 as of the end of
the period covered by this report. Based on the foregoing evaluation,  our Chief
Executive Officer has concluded that our disclosure  controls and procedures are
effective  in  timely  alerting  them to  material  information  required  to be
included in our periodic SEC filings and to ensure that information  required to
be disclosed in our periodic SEC filings is accumulated and  communicated to our
management,  including our Chief Executive  Officer,  to allow timely  decisions
regarding required disclosure.

There  was no change in our  internal  control  over  financial  reporting  that
occurred  during the fiscal  quarter  ended June 30, 2013,  that has  materially
affected,  or is reasonably  likely to materially  affect,  our internal control
over financial reporting.

                           PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

                NONE.

ITEM 1A.  RISK FACTORS

            Not Applicable to Smaller Reporting Companies.

                                       16
<PAGE>




ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the period of April 1, 2013 through  June 30,  2013,  the Company did not
make any issuances of its equity securities.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

                NONE.

ITEM 4.  MINE SAFETY DISCLOSURE

            Not Applicable.

ITEM 5.  OTHER INFORMATION

              NONE.

ITEM 6.  EXHIBITS

Exhibits.  The  following is a complete  list of exhibits  filed as part of this
Form 10-Q.  Exhibit  numbers  correspond  to the numbers in the Exhibit Table of
Item 601 of Regulation S-K.

     Exhibit 31.1  Certification of Chief Executive and Chief Financial  Officer
     pursuant to Section 302 of the Sarbanes-Oxley Act

     Exhibit 32.1  Certification  of Principal  Executive and Financial  Officer
     pursuant to Section 906 of the Sarbanes-Oxley Act

     Exhibit 101.INS  XBRL Instance Document

     Exhibit 101.SCH  XBRL Taxonomy Extension Schema Document (1)

     Exhibit 101.CAL  XBRL Taxonomy Extension Calculation Linkbase Document (1)

     Exhibit 101.DEF  XBRL Taxonomy Extension Definition Linkbase Document (1)

     Exhibit 101.LAB  XBRL Taxonomy Extension Label Linkbase Document (1)

     Exhibit 101.PRE  XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)      Pursuant to Rule 406T of Regulation S-T, this  interactive data file is
         deemed not filed or part of a registration  statement or prospectus for
         purposes of Sections 11 or 12 of the  Securities Act of 1933, is deemed
         not filed for purposes of Section 18 of the Securities  Exchange Act of
         1934, and otherwise is not subject to liability under these sections.

                                       17
<PAGE>



                                   SIGNATURES


     Pursuant to the  requirements  of Section 12 of the Securities and Exchange
Act of 1934,  the  Registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized.





                                                          GLOBAL GREEN, INC.
                                                          ------------------
                                                            (Registrant)



Dated:   August 9, 2013                 By:/s/Dr. Mehran P. Ghazvini
                                       ----------------------------------------
                                            Dr.  Mehran P. Ghazvini, DC
                                       (Principal Executive Officer,
                                        Chief Financial Officer and Principal
                                        Accounting  Officer)



                                       18